Figure 1.

CD137 increases on circulating NK cells in patients receiving mAb therapy. PBMCs were isolated from 199 patients with breast cancer (BC), head and neck cancer (HNC), and Non Hodgkin lymphoma (NHL). (A) Distribution of pre-mAb and post-mAb CD137 expression (% CD137⁺NK cells) as a box plot for each cancer type. The left panel shows pre-mAb CD137 expression and the right panel shows post-mAb CD137 expression. The horizontal line in each box shows the median value and the diamond shows the mean value. (B) Percentage of CD137⁺cells among circulating CD3^–CD56⁺NK cells from 199 patients prior to and following mAb therapy, stratified by tumor type (mean at each time point denoted by bar). ****P ≤ 0.0001.